← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Sep 2, 2026

AngioDynamics, Inc. (ANGO)

Healthcare • NASDAQ

$15.85

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

39.0/100

WEAK BUSINESS

AngioDynamics, Inc. (ANGO) scores 39/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full ANGO quality analysis & detailed breakdown

VALUATION SIGNAL

MARGIN OF SAFETY

Is this stock cheap or expensive relative to what the business has historically generated for owners?

-100.0%

Overvalued

Growth gap unavailable — insufficient data for reverse DCF calculation.

🎯 Expected Annual Return →

-43.1%

Margin of Safety convergence — your return if the market re-prices to intrinsic value (5-yr annualised)

-14.7%

Yield + growth — what the business alone earns you, even if the market never re-rates

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full ANGO valuation analysis · → View full ANGO Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-21.0%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.09x)

Operating Margin (Operational Efficiency):CRITICAL (-12.5%)

Return on Capital (Capital Efficiency):CRITICAL (-21.8%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

AngioDynamics, Inc. (ANGO) stock report — Zyberno Score 39/100 (WEAK BUSINESS), Margin of Safety -100.0%, -43% expected annual return. Full financial analysis on Zyberno.

According to Zyberno's DCF model, AngioDynamics, Inc. (ANGO) trades at $15.85 against an estimated intrinsic value per share of $0.38 — a -100.0% Margin of Safety based on Owner Earnings of $508.00K TTM, projected at 37.4% growth for 10 years with a 2.5% terminal growth rate. Zyberno's model translates this into a 5-year expected return of -43.1% annually.

Over the trailing twelve months, ANGO generated $508.00K in Owner Earnings. Capital was deployed as follows: $2.58M invested in capital expenditures. Reinvestment rate: 68.0%. Owner Earnings have grown at 37.4% annually over the trailing five years using log-linear regression.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:15.85

Market Cap:$658.18M

Valuation Multiples (3)

P/B Ratio:3.85x

P/S Ratio:2.06x

Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$624.92M

Pfcf Ratio:1,295.63x

Price Action & Momentum (3)

12-1 Momentum:

+54.5% (72th pctile)

📈 Click to view full ANGO Momentum analysis →

Momentum Percentile:72 / 100

% of 52-Week High:97.3%

B. Profitability Assessment

Return Metrics (5)

ROE:

-21.0%

📊 Click to view full ANGO ROE analysis →

ROA:-13.8%

Roic:

-21.8%

📊 Click to view full ANGO ROIC analysis →

Reinvestment Rate:68.0%

Fundamental Growth Rate (g):-14.8%

Margin Analysis (3)

Operating Margin Ttm:-12.5%

Net Margin Ttm:-11.5%

Ebitda Margin:-3.4%

TTM Performance (3)

Gross Margin Ttm:54.6%

Operating Margin Ttm:-12.5%

Net Margin Ttm:-11.5%

Yield Metrics (3)

Earnings Yield:-$5.55

Owner Earnings Yield:$0.08

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

-0.09

📊 Click to view full ANGO Earnings Surprise analysis →

EPS Surprise vs Expected:-111.3%

Latest Earnings Filed:2026-07-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-1.5%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):37.3%

Operating Cash Flow Growth Rate (Linear):27.3%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.19x

Quick Ratio:1.49x

Cash Ratio:0.72x

Leverage Analysis (3)

Debt To Equity Ttm:0.09x

Debt-to-Equity Ratio:0.09x

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:88,677,000.00

Cash And Cash Equivalents:53,864,000.00

Long Term Debt:$16.31M

Net Debt:-$33.26M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $320.17M

Linear Growth: -1.5%

📊 Click to view full ANGO Revenue analysis & methodology →

Cost Of Revenue Ttm:$145.28M

Profitability Breakdown (2)

Gross profit TTM: $174.89M

Linear Growth: 63.0%

📊 Click to view full ANGO Gross Profit analysis & methodology →

-$39.93M

Bottom Line Performance (3)

-$36.74M

Income Before Tax:-$36.30M

Ebitda Ttm:-10,781,000.00

Operating Expenses (5)

Operating Expenses:214,819,000.00

R And D Expense:29,447,000.00

Sga Expense:64,548,000.00

Income Tax Expense:$442.00K

Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:34.0%

Sga To Revenue Percentage:74.5%

Ebitda Margin:-3.4%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$267.16M

Current Assets:$163.39M

Ppe Net:27,097,000.00

Goodwill:0.00

Intangible Assets:$67.21M

Liability Structure (4)

Total Liabilities:96,338,000.00

Current Liabilities:74,717,000.00

Long Term Debt:$16.31M

Short Term Debt:$4.30M

Equity & Capital (3)

Equity:$170.83M

Retained Earnings:-$465.94M

Common Stock:75,000,000.00

Working Capital Items (3)

Accounts Receivable:48,325,000.00

Inventory:52,436,000.00

Accounts Payable:31,513,000.00

Special Items (2)

Contract Liabilities:360,000.00

Stock Based Compensation:3,915,000.00

C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $3.09M

Linear Growth: 27.3%

Free cash flow TTM: $508.00K

Linear Growth: 37.3%

📊 Click to view full ANGO Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:-$1.27M

Capital Expenditures Ttm:2,581,000.00

Financing Activities (3)

Financing Cash Flow:-$108.00K

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:29,146,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.88

-$0.88

Earnings Per Share Ttm:-$0.88

Revenue & Cash Per Share (3)

Sales Per Share Ttm:7.71

Operating Cash Flow Per Share:$0.07

Fcf Per Share Ttm:0.01

Book Value & Capital (2)

Book Value Per Share:$4.11

Cash Per Share:1.30

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.20x

Working Capital Turnover Ttm:3.61x

Receivables Management (2)

Receivables Turnover Ttm:6.63x

Days Sales Outstanding Ttm:55.09

Inventory Management (2)

Inventory Turnover Ttm:2.77x

Days Inventory Outstanding Ttm:131.74

Payables & Cash Cycle (2)

Days Payable Outstanding:79.17

Cash Conversion Cycle:107.66

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00

Quality Score:50.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Owner Earnings Analysis (3)

Owner earnings TTM: $508.00K

Linear Growth: 37.4%

📊 Click to view full ANGO Owner Earnings analysis & methodology →

Owner Earnings Per Share:$0.01

Owner Earnings Yield:$0.08

Growth Assessment (1)

Owner Earnings Growth Rate:$37.35

Damodaran Growth Analysis (2)

Reinvestment Rate:68.0%

Fundamental Growth Rate (g):-14.8%

Intrinsic Value Models (1)

Intrinsic Value:

$15.81M

📊 Click to view full ANGO DCF valuation →

Margin of Safety (1)

Margin Of Safety:

-100.0%

📊 Click to view full ANGO valuation analysis →

Return Scenarios (2)

Theoretical 5-Year Return:

-43.1%

📊 Click to view full ANGO expected return analysis →

Forward Expected Return (Yield + Growth):

-14.7%

📊 Click to view full ANGO expected return analysis →

Investment Assessment (1)

Buffett Assessment:Overvalued

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-1.5%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):37.3%

Operating Cash Flow Growth Rate (Linear):27.3%

Other Growth Rates (3)

Gross Profit Growth Rate (Linear):0.6%

Book Value Growth Rate (Linear):-23.3%

Owner Earnings Growth Rate:$37.35

C. Company Profile & Context

Corporate Information (6)

Symbol:ANGO

Company Name:AngioDynamics, Inc.

Sector:Healthcare

Industry:Medical Devices

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:medium

Volume Category:N/A

Share Structure (3)

Shares Outstanding:41.53M

Shares Outstanding Basic:41.53M

Shares Outstanding Diluted:41.53M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-09-02 00:01:49 UTC

Data Timestamp:2026-09-02T00:01:49.366627